Guido Valle

Guido Valle

Auto-generated profile, based on publicly available information

Guido Valle

Nuclear Medicine Unit, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo (FG), Italy

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MTM Torlontano
M Torlontano
UCU Crocetti
U Crocetti
LDL D'Aloiso
L D'Aloiso
NBN Bonfitto
N Bonfitto
AGA Di Giorgio
A Di Giorgio
VTVincenzo Trischitta
Vincenzo Trischitta
OBJECTIVE: The 'standard' postoperative follow-up of patients with differentiated thyroid cancer (DTC) has been based upon serum thyroglobulin (Tg) measurement and (131)I whole body scan ((131)I-WBS) after thyroid hormone (T(4)) treatment withdrawal. However, (131)I-WBS sensitivity has been reported to be low. Thyroid hormone withdrawal, often associated with hypothyroidism-related side effects, may now be replaced by recombinant human thyroid stimulating hormone (rhTSH). The aim of our study was to evaluate the diagnostic accuracy of (131)I-WBS and serum Tg measurement obtained after rhTSH stimulation and of neck ultrasonography in the first follow-up of DTC patients. DESIGN: Ninety-nine consecutive patients previously treated with total thyroidectomy and (131)I ablation, with no uptake outside the thyroid bed on the post-ablative (131)I-WBS (low-risk patients) were enrolled. METHODS: Measurement of serum Tg and (131)I-WBS after rhTSH stimulation, and ultrasound examination (US) of the neck. RESULTS: rhTSH-stimulated Tg was 1 ng/ml (Tg+) in 21 patients, including 6 patients with Tg levels >5 ng/ml. (131)I-WBS was negative for persistent or recurrent disease in all patients (i.e. sensitivity = 0%). US identified lymph-node metastases (confirmed at surgery) in 4/6 (67%) patients with stimulated Tg levels >5 ng/ml, in 2/15 (13%) with Tg>1<5 ng/ml, and in 2/78 (3%) who were Tg-negative. CONCLUSIONS: (i) diagnostic (131)I-WBS performed after rhTSH stimulation is useless in the first follow-up of DTC patients; (ii) US may identify lymph node metastases even in patients with low or undetectable serum Tg levels.

1 October 2007 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
AGAssuero Giorgetti
Assuero Giorgetti
MRMassimiliano Rossi
Massimiliano Rossi
MSMario Stanislao
Mario Stanislao
GVGuido Valle
Guido Valle
PBPietro Bertolaccini
Pietro Bertolaccini
OGon behalf of the Myoview Imaging Optimization group
on behalf of the Myoview Imaging Optimization group
The aim of this study was to investigate whether early (time 1, or T1) myocardial tetrofosmin imaging is feasible and as accurate in detecting coronary artery disease as is standard delayed (time 2, or T2) imaging. Methods: One hundred twenty patients (100 men and 20 women; mean age ± SD, 61 ± 10 y) with anginal symptoms underwent tetrofosmin gated SPECT. Stress/rest T1 imaging was performed at 15 min and T2 at 45 min after injection. Image quality was visually evaluated using a 4-point scale (from 0 = poor to 3 = optimal). Myocardial perfusion analysis was performed on a 20-segment model using quantitative perfusion SPECT software, and reversible ischemia was scored as a summed difference score (SDS). Coronary angiography was performed within 1 mo on all patients, and stenosis of more than 50% of the diameter was considered significant. Results: Overall, quality was scored as optimal or good for 94% of T1 images and 95% of T2 images (P = not statistically significant). Heart, lung, liver, and subdiaphragmatic counts did not differ for stress and rest T1 and T2 imaging. A good linear relationship was seen between T1 and T2 SDS (r = 0.69; P < 0.0001), and Bland–Altman analysis showed good agreement between the 2 conditions. In terms of global diagnostic accuracy, areas under the receiver-operating-characteristic curve were comparable between T1 and T2 (0.80 vs. 0.81, P = not statistically significant). Discrepancies between T1 and T2 SDS were observed in 44% of patients (T1 − T2 SDS > 2). Linear regression analysis showed a good correlation between T1 and T2 SDS (r = 0.67; P < 0.0001), whereas the Bland–Altman method showed a shift in the mean value of the difference of +2.67 ± 2.73. In patients with a T1 − T2 SDS of more than 2, areas under the receiver-operating-characteristic curves were significantly higher for T1 than for T2 images (0.79 vs. 0.70, P < 0.001). Conclusion: T1 imaging is feasible and as accurate as T2 imaging in identifying coronary artery disease. However, in a discrete subset of patients, early acquisition strengthens the clinical message of defect reversibility by permitting earlier, more accurate identification of more severe myocardial ischemia.

8 September 2011 in Allergy
Verified
Journal Article
Closed access
PDF file
GVG. Valle
G. Valle
MCM. Carmignani
M. Carmignani
MSM. Stanislao
M. Stanislao
AFA. Facciorusso
A. Facciorusso
AVA. R. Volpe
A. R. Volpe

1 March 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SPSalvatore Parisi
Salvatore Parisi
PCPietro Corsa
Pietro Corsa
ARArcangela Raguso
Arcangela Raguso
APAntonio Perrone
Antonio Perrone
SCSabrina Cossa
Sabrina Cossa
GVGuido Valle
Guido Valle
Temozolomide (TMZ) is the first line drug in the care of high grade gliomas. The combined treatment of TMZ plus radiotherapy is more effective in the care of brain gliomas then radiotherapy alone. Aim of this report is a survival comparison, on a long time (>10 years) span, of glioma patients treated with radiotherapy alone and with radiotherapy + TMZ.Materials and Methods. In this report we retrospectively reviewed the outcome of 128 consecutive pts with diagnosis of high grade gliomas referred to our institutions from April 1994 to November 2001. The first 64 pts were treated with RT alone and the other 64 with a combination of RT and adjuvant or concomitant TMZ.Results. Grade 3 (G3) haematological toxicity was recorded in 6 (9%) of 64 pts treated with RT and TMZ. No G4 haematological toxicity was observed. Age, histology, and administration of TMZ were statistically significant prognostic factors associated with 2 years overall survival (OS). PFS was for GBM 9 months, for AA 11.Conclusions. The combination of RT and TMZ improves long term survival in glioma patients. Our results confirm the superiority of the combination on a long time basis.

26 October 2015 in Endocrine
Verified
Journal Article
Closed access
PDF file
Vincenzo TriggianiVincenzo Triggiani
Vincenzo Triggiani
VGVito Angelo Giagulli
Vito Angelo Giagulli
MIMichele Iovino
Michele Iovino
GPGiovanni De Pergola
Giovanni De Pergola
BLBrunella Licchelli
Brunella Licchelli
EGEdoardo Guastamacchia
Edoardo Guastamacchia

23 April 2014
Verified
Closed access
MCM Carmignani
M Carmignani
AVA R Volpe
A R Volpe
MAM Aldea
M Aldea
OSO Soritau
O Soritau
AIA Irimie
A Irimie
GVGuido Valle
Guido Valle